Shanghai MicroPort Endovascular MedTech Co., Ltd.

SHSE:688016 Stock Report

Market Cap: CN¥12.8b

Shanghai MicroPort Endovascular MedTech Future Growth

Future criteria checks 4/6

Shanghai MicroPort Endovascular MedTech is forecast to grow earnings and revenue by 20.3% and 29.2% per annum respectively. EPS is expected to grow by 19.2% per annum. Return on equity is forecast to be 17.5% in 3 years.

Key information

20.3%

Earnings growth rate

19.2%

EPS growth rate

Medical Equipment earnings growth26.7%
Revenue growth rate29.2%
Future return on equity17.5%
Analyst coverage

Good

Last updated11 Nov 2024

Recent future growth updates

Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts

Aug 29
Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts

Recent updates

Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Attractive Earnings Are Not All Good News For Shareholders

Nov 06
Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Attractive Earnings Are Not All Good News For Shareholders

There's No Escaping Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Muted Earnings Despite A 31% Share Price Rise

Oct 01
There's No Escaping Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Muted Earnings Despite A 31% Share Price Rise

Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts

Aug 29
Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts

Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Aug 15
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

Jun 29
Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Apr 29
These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Apr 09
Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Mar 25
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Earnings and Revenue Growth Forecasts

SHSE:688016 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,3119714869448
12/31/20251,7697512897269
12/31/20241,1805771845553
9/30/20241,268657390606N/A
6/30/20241,353616437636N/A
3/31/20241,260552458651N/A
12/31/20231,187492368558N/A
9/30/20231,121444166398N/A
6/30/20231,05942122369N/A
3/31/2023924358-10308N/A
12/31/202289735740334N/A
9/30/2022839367133340N/A
6/30/2022781346276362N/A
3/31/2022745338242337N/A
12/31/2021685316211300N/A
9/30/2021652302248299N/A
6/30/2021618279255291N/A
3/31/2021569257239269N/A
12/31/2020470215191217N/A
9/30/2020414192148174N/A
6/30/2020377177142166N/A
3/31/2020341156133154N/A
12/31/2019334142122143N/A
9/30/2019306127117138N/A
6/30/201928211584117N/A
3/31/201925710390118N/A
12/31/20182319182107N/A
12/31/201716563N/A69N/A
12/31/201612541N/A30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688016's forecast earnings growth (20.3% per year) is above the savings rate (2.8%).

Earnings vs Market: 688016's earnings (20.3% per year) are forecast to grow slower than the CN market (26% per year).

High Growth Earnings: 688016's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688016's revenue (29.2% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 688016's revenue (29.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 688016's Return on Equity is forecast to be low in 3 years time (17.5%).


Discover growth companies